Norveška - norveščina - Statens legemiddelverk

berlin-chemie ag / menarini - dapoksetinhydroklorid - tablett, filmdrasjert - 30 mg

Evropska unija - norveščina - EMA (European Medicines Agency)

stemline therapeutics b.v. - tagraxofusp - lymphoma - antineoplastiske midler - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).

Evropska unija - norveščina - EMA (European Medicines Agency)

stemline therapeutics b.v. - selinexor - multippelt myelom - antineoplastiske midler - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Evropska unija - norveščina - EMA (European Medicines Agency)

stemline therapeutics b.v. - elacestrant - bryst neoplasms - endokrin terapi - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

Evropska unija - norveščina - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - umeclidinium bromide, vilanterol trifenatate - lungesykdom, kronisk obstruktiv - legemidler for obstruktive sykdommer i luftveiene, - anoro ellipta er angitt som en vedlikehold bronkodilaterende behandling for å lindre symptomer hos voksne pasienter med kronisk obstruktiv lungesykdom (kols).

Evropska unija - norveščina - EMA (European Medicines Agency)

covis pharma europe b.v. - aclidinium bromide - lungesykdom, kronisk obstruktiv - legemidler for obstruktive sykdommer i luftveiene, - bretaris genuair er indikert som en vedlikeholdsbronkodilatorbehandling for å lindre symptomer hos voksne pasienter med kronisk obstruktiv lungesykdom (kol).

Evropska unija - norveščina - EMA (European Medicines Agency)

covis pharma europe b.v. - formoterol fumarate dihydrate, aclidinium bromide - lungesykdom, kronisk obstruktiv - legemidler for obstruktive sykdommer i luftveiene, - brimica genuair er indikert som vedlikeholdsbronkodilatorbehandling for luftstrømningsobstruksjon og lindring av symptomer hos voksne pasienter med kronisk obstruktiv lungesykdom (kol).

Evropska unija - norveščina - EMA (European Medicines Agency)

substipharm - prasugrel - acute coronary syndrome; angina, unstable; myocardial infarction - antithrombotic agents - efient, co administreres med acetylsalisylsyre (asa), angis for forebygging av aterotrombotiske hendelser hos pasienter med akutt koronarsyndrom (jeg. ustabil angina, ikke-st-segmentet-elevation hjerteinfarkt [ua / nstemi] eller st-segmentet-elevation hjerteinfarkt [stemi]) under primær eller forsinket pci-behandling (pci).

Evropska unija - norveščina - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - umeclidiniumbromid - lungesykdom, kronisk obstruktiv - legemidler for obstruktive sykdommer i luftveiene, - indikeres som en vedlikeholdsbronkodilatorbehandling for å lindre symptomer hos voksne pasienter med kronisk obstruktiv lungesykdom (kol).

Evropska unija - norveščina - EMA (European Medicines Agency)

janssen-cilag international nv - canagliflozin - diabetes mellitus, type 2 - legemidler som brukes i diabetes - invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 og 5.